NLE1

Across TCGA pan-cancer cohorts, NLE1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NLE1 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NLE1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NLE1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where NLE1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.466	0.920	.002	13	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.575	.007	12	view →
LUAD	DFS	Tertile	III,IV	0.846	0.187	.015	12	view →
HNSC	OS	Quartile	All	0.739	0.899	.008	10	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NLE1–CCRCC (DFS)

Open the CCRCC breakdown →